Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
RTNominal down7.870 -0.230 (-2.840%)
Research Report

31/12/2020 15:01

{I-bank focus}Huatai starts Sino Biopharm at HK$10.58

[ET Net News Agency, 31 December 2020] Huatai Research initiated coverage on Sino
Biopharmaceutical (SNB) (01177) with a "buy" rating and a target price of HK$10.58.
The research house said SNB is one of the largest-scale pharmaceutical companies,
equipped with leading commercial and R&D teams, in China. Huatai favors SNB's evolution
into a novel drug-driven company, considering the solid sales growth of anlotinib and a
robust pipeline led by PD-1/PD-L1 mAbs and small molecular drugs.
It forecast SNB's revenue at RMB23.8bn/RMB27.2bn/RMB32.1bn in 2020/21/22 with a two-year
CAGR of 16.1% and net profit at RMB2.7bn/RMB3.2bn/RMB3.8bn with a two-year CAGR of 18.7%.

Remark: Real time quote last updated: 12/04/2021 12:25
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2021 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.